Examination concerning preventive maintenance of the Age Degeneration of Maculae, AMD

  Some clinical trials of a degeneration of maculae now in an embodying stage. The most promising approach - treatment of an antiangiogenesis for the damp degeneration of maculae. Various strategy of an antiangiogenesis which block the VEGF-mediated choroidal neovascularization, are estimated in clinical trials. Preparations now, maculae approved for the damp degeneration, include: pegaptanib (Macugen). Preparations at examination include: ranibizumab (Lucentis), anecortave (Retaane), bevacizumab (Avastin), squalamine (Evizon) and siRNA. The second generation antisensory oligonucleotides iCo-007 planning for kinazy Raf-1 also is investigated as the purpose for wide inhibition of plural proangiogenic signals. Most promising of this treatment, ranibizumab (Lucentis), is 1st medical product which has been checked up which has shown the considerable recover of visual acuteness in a plural phase experiments. Radiation therapy (brachytherapy) and rheopheresis also are estimated on the damp degeneration of maculae.

  Recent examinations guess, that statins, the family of the preparations, used to reduce cholesterol levels, can be effective in preventive maintenance AMD, and in retardation of its progression.

  Age Eye Examination of Illness has concluded, that high levels of antioxidants and zinc can reduce hazard of some people of development premature AMD approximately to 25 percent. In 2006 AREDS goes at full speed to study effects Genistein (a derivative in Soyabeans).